1. SWOG S0709: Randomized Phase II Trial of Erlotinib versus Erlotinib Plus Carboplatin/Paclitaxel in Patients with Advanced Non–Small Cell Lung Cancer and Impaired Performance Status as Selected by a Serum Proteomics Assay 
Primo N. Lara, MD, James Moon, MS, Paul J. Hesketh, MD, Mary W. Redman, PhD, Stephen K. Williamson, MD, Wallace L. Akerley, MD, Fred R. Hirsch, MD, PhD, Philip C. Mack, PhD, David R. Gandara, MD 
Journal of Thoracic Oncology 
Volume 11, Issue 3, Pages (March 2016)
DOI: /j.jtho
Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

2. Figure 1
Study scheme. Patients were seen for toxicity assessment before the start of every cycle. Version 4.0 of the National Cancer Institute's Common Terminology Criteria for Adverse Events was used for reporting serious adverse events, whereas version 3.0 was used for reporting routine toxicity. Response assessments were based on the Response Evaluation Criteria for Solid Tumors, version 1.1.
Journal of Thoracic Oncology  , DOI: ( /j.jtho )
Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

3. Figure 2
Kaplan-Meier survival curves for progression-free and overall survival.
Journal of Thoracic Oncology  , DOI: ( /j.jtho )
Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions